Insider · CIK 0001696711
Kairos Venture Partners II, L.P.
Files at ACTU (ACTUATE THERAPEUTICS, INC.). First filing -, latest -.
In brief
Kairos Venture Partners II, L.P. files SEC Form 4 as director and 10% owner at ACTU (ACTUATE THERAPEUTICS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Kairos Venture Partners II, L.P. has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 11, 2025 | ACTU Actuate Therapeutics, Inc. | 280,000 1.20% of outstanding | $2.1M | Dec 11, 2025 | none |
Transactions
Every row this insider has filed, 0 in all, newest first.
Questions about Kairos Venture Partners II, L.P.
Answered from the filings on this page, as of the latest one.
Is Kairos Venture Partners II, L.P. buying or selling?
Kairos Venture Partners II, L.P. has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Kairos Venture Partners II, L.P.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kairos Venture Partners II, L.P. has 0.
Where does Kairos Venture Partners II, L.P. file Form 4?
Kairos Venture Partners II, L.P. has filed Form 4 at ACTU (ACTUATE THERAPEUTICS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.